These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Safety of quinolones administration in children?]. Danés I; Arnau JM Med Clin (Barc); 2001 Nov; 117(17):676-7. PubMed ID: 11734174 [No Abstract] [Full Text] [Related]
3. Quinolones in children. Are concerns over arthropathy justified? Stahlmann R; Förster C; Van Sickle D Drug Saf; 1993 Dec; 9(6):397-403. PubMed ID: 8129861 [No Abstract] [Full Text] [Related]
4. [Question marks about the use of enrofloxacin in sport horses]. Oostra F Tijdschr Diergeneeskd; 2003 Feb; 128(4):124. PubMed ID: 12625163 [No Abstract] [Full Text] [Related]
5. Children as a special population at risk--quinolones as an example for xenobiotics exhibiting skeletal toxicity. Stahlmann R Arch Toxicol; 2003 Jan; 77(1):7-11. PubMed ID: 12491034 [TBL] [Abstract][Full Text] [Related]
6. [Iatrogenic rheumatic diseases]. Buchard PA Rev Med Suisse Romande; 2004 Sep; 124(9):551-5. PubMed ID: 15552749 [TBL] [Abstract][Full Text] [Related]
7. The pharmacological management of drug-induced rheumatic disorders. di Fazano CS; Bertin P Expert Opin Pharmacother; 2001 Oct; 2(10):1623-31. PubMed ID: 11825305 [TBL] [Abstract][Full Text] [Related]
8. Prevalence of rheumatic diseases in a rheumatological outpatient practice. Vanhoof J; Declerck K; Geusens P Ann Rheum Dis; 2002 May; 61(5):453-5. PubMed ID: 11959771 [TBL] [Abstract][Full Text] [Related]
9. Safety profile of the quinolones. Stahlmann R J Antimicrob Chemother; 1990 Nov; 26 Suppl D():31-44. PubMed ID: 2286589 [TBL] [Abstract][Full Text] [Related]
12. Rheumatological complications associated with the use of indinavir and other protease inhibitors. Florence E; Schrooten W; Verdonck K; Dreezen C; Colebunders R Ann Rheum Dis; 2002 Jan; 61(1):82-4. PubMed ID: 11779768 [TBL] [Abstract][Full Text] [Related]
13. Use of the new quinolones in pediatrics. Schaad UB Isr J Med Sci; 1994; 30(5-6):463-8. PubMed ID: 8034505 [TBL] [Abstract][Full Text] [Related]
14. Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy. Liew DFL; Leung JLY; Liu B; Cebon J; Frauman AG; Buchanan RRC Int J Rheum Dis; 2019 Feb; 22(2):297-302. PubMed ID: 30549256 [TBL] [Abstract][Full Text] [Related]
15. [Cartilage-damaging effect of quinolones]. Stahlmann R Infection; 1991; 19 Suppl 1():S38-46. PubMed ID: 2007514 [TBL] [Abstract][Full Text] [Related]
16. Quinolone arthropathy in immature rabbits treated with the fluoroquinolone, PD 117596. Gough A; Johnson R; Campbell E; Hall L; Tylor J; Carpenter A; Black W; Basrur PK; Baragi VM; Sigler R; Metz A Exp Toxicol Pathol; 1996 Jun; 48(4):225-32. PubMed ID: 8811288 [TBL] [Abstract][Full Text] [Related]
17. Risk/benefit analysis of quinolone use in children: the effect on diarthrodial joints. Maggiolo F; Caprioli S; Suter F J Antimicrob Chemother; 1990 Oct; 26(4):469-71. PubMed ID: 2254219 [No Abstract] [Full Text] [Related]
18. [Arthrotoxicity of quinolones and fluoroquinolones in experiment:character of lesion and mechanism of action]. Padeĭskaia EN Antibiot Khimioter; 2000; 45(8):36-41. PubMed ID: 10989723 [No Abstract] [Full Text] [Related]
19. [Articular chondroprotection]. Borrachero del Campo J An R Acad Nac Med (Madr); 1987; 104(4):467-80. PubMed ID: 3328523 [No Abstract] [Full Text] [Related]